Predicting Death in ICU Patients with Multidrug-Resistant Gram-Negative Infections
Official title: Design of a Predictive Model of Mortality in Critically Ill Patients Colonized by Multiresistant Gram-negative Bacteria. MR-GEIPC STUDY
Run by Fundacion SEIMC-GESIDA · NCT07749508 · Data updated 2026-11-12
This study tests whether a Mortality risk model can predict outcomes for critically ill adults in the ICU who are colonized or infected with multidrug-resistant Gram-negative bacteria.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Fundacion SEIMC-GESIDA Academic / other |
| Locations | 1 site (Madrid, Madrid) |
| Status | Recruiting |
| Started | March 2, 2026 |
| Main results expected | May 31, 2027 |
| Study ends | May 31, 2027 |
| Registry record updated | August 6, 2026 |
| Trial ID | NCT07749508 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) admitted to the ICU, with ESBL-producing Enterobacteriaceae, carbapenemase-producing organisms, Pseudomonas aeruginosa, or MDR Acinetobacter baumannii, or non-colonized patients for the control group.
✕Probably not a fit
Patients without MDR-GNB colonization or infection and those not receiving standard of care may see limited applicability of the predictive model.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter observational study. It aims to develop a predictive model of mortality among critically ill, MDR-GNB-colonized patients. The study collects data on infectious complications, their causes, and their impact on prognosis, including comparisons with non-colonized ICU patients included in the first month. Data are gathered from standard-of-care practices across participating centers, focusing on events such as bacteremia and pneumonia, with priority given to the most impactful infections. Analyses will consider severity of illness and need for artificial support.
Why it matters
Potential benefit: If successful, the model could help clinicians identify high-risk patients early and tailor monitoring and treatments accordingly.
How similar studies have gone: Previous observational efforts have shown promise in risk stratification for ICU infections, but this particular predictive model for MDR-GNB colonization is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged ≥18 years * Have given informed consent. Exclusion Criteria: * Patients who do not agree to participate in the study * Admission to the ICU \< 24 hours
Where it's running
-
Hospital Universitario La Paz
Madrid, Madrid, Spain Recruiting
Study contacts
- Study coordinator: Montserrat Aguirregabiria, Principal Investigator
- Email: montseara17@gmail.com
- Phone: 034687428599
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.